Interview with Charlotte Teunissen on VJN

  • News

October 14, 2021

Charlotte Teunissen, PhD, VU University Medical Center Amsterdam, The Netherlands, has recently discussed ongoing work in her group, looking to identify novel treatment response biomarkers for progressive multiple sclerosis (MS). Using Olink technology for multiplex protein biomarker discovery, Prof. Teunissen’s team are analyzing data from patients treated with natalizumab or ocrelizumab, hoping to discover markers that distinguish individuals with persistent progression from those with controlled disease.

Prof. Teunissen also discussed their plans to prepare for the implementation of novel biomarkers, such as defining detailed protocols for pre-analytical handling of samples for contactin 1 and GFAP analysis. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021 and was presented by the Video Journal of Neurology.

2947

Biomarker assays

~475 million

Protein data points generated

662

Publications listed on website

35

Certified Core Labs

Contact us!